What Alentis Therapeutics does

Alentis Therapeutics is a clinical-stage Swiss-French biotechnology company developing first-in-class therapeutics that target exposed Claudin-1 (CLDN1) for the treatment of cancer and organ fibrosis. Founded in 2019 and headquartered at the Swiss Innovation Park in Allschwil, Switzerland, with research operations in Strasbourg, France, and clinical operations in the United States, the company serves patients with Claudin-1 positive (CLDN1+) solid tumors—including head and neck squamous cell carcinoma (HNSCC), lung, cervical, and esophageal cancers—and patients suffering from organ fibrosis affecting the liver, kidney, and lung. Leadership transitioned in October 2025 with the appointment of Mark Pruzanski, founder and former CEO of Intercept Pharmaceuticals, as CEO.

The company's pipeline rests on a proprietary Claudin-1 platform spanning both monoclonal antibodies and antibody-drug conjugates (ADCs). Its clinical assets include Lixudebart (ALE.F02), a monoclonal antibody designed to reverse fibrosis by blocking fibrotic signaling and remodeling the collagen barrier; ALE.C04, a monoclonal antibody for CLDN1+ tumors in Phase 1/2 for HNSCC; ALE.P02, a first-in-class ADC linking an anti-CLDN1 antibody to a tubulin inhibitor payload for CLDN1+ squamous solid tumors; and ALE.P03, a first-in-class ADC with a topoisomerase I inhibitor payload for CLDN1+ solid tumors. The platform has secured two FDA Fast Track designations (ALE.C04 in 2023, ALE.P02 in 2024), one FDA Orphan Drug designation (lixudebart for IPF in 2024), and two FDA IND clearances (ALE.C04 in 2023, ALE.P02 in 2024), with positive topline Phase 1b/Phase 2 data for lixudebart in ANCA-RPGN and advanced liver fibrosis reported in January 2025.

As a privately held, pre-commercial company, Alentis does not currently generate product revenue. Its business model is to advance investigational therapies through clinical trials and ultimately out-license, partner, or commercialize them via standard pharmaceutical channels. The company has raised approximately $353 million in equity across Series B, C, and D rounds (plus a CHF 2.4M Innosuisse grant), with a top-tier syndicate including OrbiMed, Novo Holdings, Jeito Capital, RA Capital Management, Frazier Life Sciences, and Longitude Capital. Recent leadership additions—CFO Jonathan Freve (September 2024), CEO Mark Pruzanski (October 2025), and General Counsel/CAO Bryan Yoon and CBO Aditya Venugopal (November 2025)—signal organizational maturation in preparation for late-stage clinical execution and a potential strategic transaction or public offering.

Name

Alentis Therapeutics

Legal name

Alentis Therapeutics AG

Website

https://alentis.ch

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Alentis Therapeutics is a clinical-stage Swiss-French biotechnology company developing first-in-class anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies to treat Claudin-1 positive solid tumors and reverse organ fibrosis in liver, kidney, and lung.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Antibody-drug conjugates
• Monoclonal antibody therapy
• Oncology therapeutics
• Organ fibrosis treatment
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Allschwil

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Marketing channels11 records

Core offering

Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class anti-Claudin-1 (CLDN1) antibody-drug conjugates (ADCs) and monoclonal antibodies. Its pipeline targets CLDN1+ solid tumors (head and neck, lung, cervical, esophageal cancers) and organ fibrosis (liver, kidney, lung) through mechanisms that remodel the extracellular matrix, block disease signaling, and selectively kill tumor cells or reverse fibrotic tissue.

Product overview

Alentis Therapeutics is a clinical-stage biotech company developing a portfolio of first-in-class anti-Claudin-1 (CLDN1) antibody-drug conjugates (ADCs) and monoclonal antibodies for treating CLDN1+ solid tumors and organ fibrosis. The product portfolio includes: Lixudebart (ALE.F02), a monoclonal antibody for liver, kidney, and lung fibrosis; ALE.C04, a monoclonal antibody for CLDN1+ tumors; ALE.P02, an ADC with tubulin inhibitor payload for squamous cancers; and ALE.P03, an ADC with topoisomerase I inhibitor payload for solid tumors. The company operates a unified platform approach centered on targeting exposed CLDN1, with programs spanning both oncology and fibrosis indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Lixudebart (ALE.F02) First-in-class monoclonal antibody designed to reverse organ fibrosis in liver, kidney, and lung by targeting exposed Claudin-1 (CLDN1), blocking fibrotic signaling, and opening the collagen barrier. For patients with advanced liver fibrosis, ANCA-associated vasculitis, and idiopathic pulmonary fibrosis.
• ALE.C04 First-in-class monoclonal antibody targeting exposed CLDN1 on cancer cells, designed to treat cancer through remodeling of extracellular matrix and direct tumor cell killing via effector function. For patients with CLDN1+ tumors, particularly head and neck squamous cell carcinoma (HNSCC).
• ALE.P02
• ALE.P03

Quantifiable outcome

• Dose-dependent target engagement demonstrated in Phase 1b liver fibrosis and Phase 2 ANCA-RPGN studies
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• University of Strasbourg / InsermcoreStrategic or Co-development PartnerCompany was founded based on ground-breaking research from Prof. Thomas Baumert's laboratory at the University of Strasbourg and French National Institute of Health and Medical Research (Inserm). Ongoing research collaboration.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bicycle Therapeutics: Clinical-stage biotech developing bicyclic antibody-based therapeutics and toxin conjugates (Bicyclics) for oncology. Closely comparable to Alentis as a clinical-stage ADC/antibody-conjugate platform company with similar size and capital profile.
• Mersana Therapeutics: Clinical-stage biotech developing ADCs with proprietary Dolasynthen and Immunosynthen platforms targeting oncology. Directly comparable as a clinical-stage ADC developer of similar size, stage, and indication focus.
• Pliant Therapeutics: Clinical-stage biotech developing integrin-targeting therapies for fibrotic diseases including IPF and PSC. Directly comparable to Alentis's lixudebart fibrosis program in indication, stage, and business model.
• Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies built around novel tumor targets. Comparable clinical-stage antibody/ADC oncology company with similar stage and pipeline breadth.
• MacroGenics: Clinical-stage biotech developing monoclonal antibodies and ADCs for cancer using proprietary DART and TRIDENT platforms. Comparable antibody-based oncology company with overlapping technology approach and indication scope.

Broad incumbents

• AbbVie: Global biopharmaceutical company with established IPF franchise (OFEV/Esbriet via legacy Boehringer deal and Elahere ADC). Comparable broad incumbent in fibrosis and ADC oncology with overlapping competitive scope.
• Daiichi Sankyo: Japanese pharma pioneer in ADC development with Enhertu (HER2/HER3 DXd platform) and Datroway. Relevant as broad incumbent in ADC space where Alentis's ALE.P02 and ALE.P03 would compete for share and clinical precedence.
• Roche: Global pharma with extensive ADC portfolio (Kadcyla), HNSCC franchise (Erbitux), and fibrosis research programs. Comparable broad incumbent in ADC oncology and organ fibrosis where several Alentis board members previously worked.
• Galapagos NV: Mid-cap European biotech focused on fibrosis and inflammation with IPF and systemic sclerosis programs. Comparable as a larger fibrosis-focused player operating in the same indications as Alentis's lixudebart.
• FibroGen: Clinical-stage biotech developing therapies for fibrotic diseases and anemia, with prior IPF and Duchenne programs. Comparable as broader fibrosis-focused player in adjacent indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCTH5dLP_r1eN6zaujt7vaew
• LinkedInlinkedin.com/company/alentis-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alentis Therapeutics